Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Journal Abstract

Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.

Publication Date: 2024 Aug 13

Full Text Sources

Authors

T M Kim; M Taszner; S Novelli; S-G Cho; J C Villasboas; M Merli; A Jiménez-Ubieto; B Tessoulin; L M Poon; D Tucker; J Walewski; S Yi; Y Song; G Chong; E Bachy; S Guidez; A Alonso; D Jagadeesh; W Zhang; L Magnano; E Iskierka-Jażdżewska; M Tani; B Shen; A Uppala; M Zhu; S Shariff; J Brouwer-Visser; A Chaudhry; H Mohamed; S Ambati; S Luminari

Abstract

OBJECTIVE

Odronextamab, a CD20×CD3 bispecific antibody that engages cytotoxic T cells to destroy malignant B cells, has demonstrated encouraging activity across multiple subtypes of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma.

Source

Annals of oncology : official journal of the European Society for Medical Oncology

Pub Types(s)

Journal Article

Language

English

PubMed ID

39147364